手法治疗用于头颈癌幸存者纤维化相关迟发性吞咽困难:MANTLE非随机临床试验
这项前瞻性单中心单臂先导试验纳入24例头颈癌放疗后2年以上的幸存者,评估手法治疗(MT)的可行性、安全性及对颈部活动度(CROM)和吞咽功能的影响。22例(91.7%)完成10次治疗,1例发生严重不良事件;完成者最大张口度(MIO)和6个平面CROM均有大效应量改善,患者报告结局改善为中至大效应量,但未补偿吞咽结局效应量小至中等或无效。
要点
- 22例(91.7%)完成10次手法治疗,1例发生严重不良事件,达到75%可行性目标。
- 完成治疗者MIO(r=0.76;95%CI 0.66-0.94)和6个平面CROM均大效应量改善。
- 患者报告结局改善为中至大效应量,未补偿吞咽结局效应量小至中等或无效。
核心结论
- 本研究发现MT在伴有迟发性放射性吞咽困难的长期头颈癌幸存者中安全可行,并与多项功能、躯体和社会心理获益相关。
- 该试验可能为将MT整合入综合康复方案以优化吞咽结局的下一步方向提供启示。
研究设计与样本
- MANTLE为前瞻性、单机构、先导性、单臂支持治疗非随机临床试验,在National Comprehensive Cancer Network认定的学术综合癌症中心开展。
- 纳入成人头颈癌幸存者,要求治愈性放疗后2年及以上无病,纤维化按CTCAE v4.0为2级及以上,吞咽困难按视频透视DIGEST为2级及以上。
- 干预为6周内由淋巴水肿认证言语语言病理学家实施10次每小时MT,并配合家庭锻炼计划;随后6周洗脱期仅实施家庭锻炼计划,无临床医生MT。
- 数据收集于2018年6月至2021年7月,分析于2022年11月至2024年11月。
- 主要终点为可行性(以治疗完成率衡量,目标75%)和安全性。
主要发现
- 24例头颈癌幸存者中20例男性(83.3%),中位(范围)年龄68(53-80)岁,治愈性放疗后中位(范围)8.9(2.4-30.2)年。
- 22例(91.7%)完成10次既定治疗,1例发生严重不良事件。
- 完成治疗者MIO改善(r=0.76;95%CI 0.66-0.94),全部6个平面CROM改善(如颈椎后伸:r=0.86;95%CI 0.83-0.93),从基线至MT后均为大效应量。
- 患者报告结局的症状指标达中至大效应量(如MT后淋巴水肿-纤维化症状严重度:r=0.74;95%CI 0.63-0.99)。
- 未补偿吞咽结局指标效应量为小至中等或无效(如MD Anderson吞咽困难量表综合评分从基线至MT后:r=0.38;95%CI 0.07-0.73)。
关键数值与推荐
- 可行性目标为治疗完成率75%;实际22例(91.7%)完成10次治疗。
- 安全性:1例参与者发生严重不良事件。
- MIO从基线至MT后r=0.76(95%CI 0.66-0.94)。
- 颈椎后伸从基线至MT后r=0.86(95%CI 0.83-0.93)。
- MD Anderson吞咽困难量表综合评分从基线至MT后r=0.38(95%CI 0.07-0.73)。
临床怎么用
- 作者认为MT在伴有迟发性放射性吞咽困难的长期头颈癌幸存者中安全可行,并与多项功能、躯体和社会心理获益相关。
- 作者提出该试验可能为将MT整合入综合康复方案以优化吞咽结局的下一步方向提供启示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Late radiation-associated dysphagia (RAD) after head and neck cancer (HNC) treatment is challenging and commonly treatment refractory, with fibrosis stiffening connective tissues and compressing peripheral nerve tracts, contributing to diminished strength and possibly denervation of swallowing muscles. Manual therapy (MT), while common for cancer-related pain and other indications, remains largely unstudied for fibrosis-related late RAD. OBJECTIVE: To determine the feasibility and safety of MT, estimate effect size and durability of MT for associated improvements in cervical range of motion (CROM), and examine functional outcomes after MT in survivors of HNC with fibrosis-related late RAD. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial, Manual Therapy for Fibrosis-Related Late Effect (MANTLE) Dysphagia in Head and Neck Cancer Survivors, is a prospective, single-institution, pilot, single-arm supportive care trial conducted at a National Comprehensive Cancer Network-designated academic comprehensive cancer center. Participants were adult survivors of HNC who were disease free at 2 or more years after curative-intent radiotherapy with grade 2 or higher fibrosis (per Common Terminology Criteria for Adverse Events version 4.0) and grade 2 or higher dysphagia (per video fluoroscopy Dynamic Imaging Grade of Swallowing Toxicity [DIGEST]). Data were collected June 2018 to July 2021 and analyzed November 2022 to November 2024. INTERVENTION: MANTLE included 10 hourly MT sessions by lymphedema-certified speech-language pathologists over 6 weeks with a home exercise program. During the subsequent 6-week washout period, participants implemented only the home exercise program, without clinician MT. OUTCOMES AND MEASURES: Primary end points were feasibility (per therapy completion rate, with a 75% target) and safety. Secondary end points included functional outcomes per CROM, dysphagia severity (per DIGEST), maximum interincisal opening (MIO), and validated participant-reported outcomes (PROs). RESULTS: Among 24 survivors of HNC (20 male [83.3%]; median [range] age, 68 [53-80] years), there was a median (range) of 8.9 (2.4-30.2) years after curative-intent radiotherapy. A total of 22 participants (91.7%) completed the 10 prescribed therapy sessions, and 1 participant experienced a severe adverse event. Secondary end points improved among participants who completed the therapy: MIO (r = 0.76; 95% CI, 0.66 to 0.94) and all 6 planes of CROM (eg, cervical extension: r = 0.86; 95% CI, 0.83 to 0.93) improved, with large effect sizes from baseline to after MT. Large to moderate effect sizes were achieved in symptom measures per PROs (eg, lymphedema-fibrosis symptom severity after MT: r = 0.74; 95% CI, 0.63 to 0.99). However, effect sizes were small to moderate or null in uncompensated swallowing outcome measures (eg, MD Anderson Dysphagia Inventory composite score from baseline to after MT: r = 0.38; 95% CI, 0.07 to 0.73). CONCLUSIONS: This study found that MT was safe and feasible in long-term survivors of HNC with late RAD and was associated with several functional, physical, and psychosocial gains. This trial may offer insight into next directions to optimize swallowing outcomes by integrating MT into a comprehensive rehabilitation program. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03612531.
引用
- McMillan H, Warneke CL, Buoy S, et al. Manual Therapy for Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors: The MANTLE Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39913160. doi:10.1001/jamaoto.2024.5157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。